
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells



- highly synergistic cytotoxic activity via endoplasmatic reticulum stress-induced apoptosis
- prolonged proteasome inhibition
- increased activation of the unfolded protein response
- increased activation of IRE1-α activity